PSG RxWIRE Newsletter – December 1, 2016

Creating opportunity for our clients with an exclusive focus on pharmacy solutions.

House to Vote on Bill Aimed at Speeding Drug Approvals

Associated Press - November 29

The House plans to vote Wednesday on a $6.3 billion bill aimed at speeding federal approval of drugs and medical devices and boosting biomedical research.

READ MORE

Trump's picks for HHS and CMS signal a move to barrel through ACA repeal and replacement

Modern Healthcare - November 28

President-elect Donald Trump's selections for the top healthcare posts in the federal government signal an appetite to move aggressively to repeal and replace the Affordable Care Act, overhaul Medicare and give states more control over Medicaid.

READ MORE

SUMMARY OF TOP ARTICLES

Amgen eyes spending caps to win payer nods on migraine prospect erenumab

FiercePharma - November 21

Note to drugmakers negotiating with payers: It's not the price tag that's the problem, or at least not by itself.

Do cancer clinical trials exaggerate the real-world benefits of drugs?

STAT - November 21

The large clinical trials needed for federal approval of new cancer drugs often way overstate how effective the treatments will be in the real world, two cancer physicians argued recently in JAMA Oncology.

Two more cancer patients just died in a clinical trial. Should the FDA be blamed?

STAT - November 23

When three cancer patients died earlier this year while on an experimental therapy, the Food and Drug Administration promptly halted the clinical trial. A few days later, the hold was lifted — a turnaround so fast that it stunned the world of drug development.

340B Compliance: Tips to Maintaining a Successful Program

Pharmacy Times - November 22

Since its induction in 1992, the 340B Drug Pricing Program, managed by the Health Resources and Services Administration (HRSA), has been responsible for helping eligible covered entities stretch scarce federal resources and increase services to patients of the covered entity.

Integrating pharmacy benefit, medical benefit cuts costs

Managed Healthcare Executive - November 29

Managed care executives should attend to the comprehensive management of drugs that are covered on both the pharmacy benefit and medical benefit because both benefits contribute significantly to cost trends, according to one industry expert.

Common Drugs Boost Diabetes Risk in RA Patients

MedPage Today - November 25

Patents treated for rheumatoid arthritis (RA) should be monitored over the long term for diabetes mellitus, according to a large longitudinal databank study in Annals of the Rheumatic Diseases.

These Medicines Often Send Americans to ERs

HealthDay News - November 22

An estimated one in 250 Americans lands in the hospital emergency department each year because of a medication-related reaction or problem, a new federal study finds.

Bonus From Your Blood Pressure Med: Fewer Fractures?

HealthDay News - November 21

High blood pressure and weakened bones are two big health issues for seniors.

FDA NEWS

Sanofi Receives FDA Approval of Soliqua(TM) 100/33, for the Treatment of Adults with Type 2 Diabetes

Globe Newswire - November 21

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua(TM) 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide.

Daratumumab (DARZALEX)

FDA - November 21

On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen

Biotech, Inc.) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Novo Nordisk receives US FDA approval for Xultophy® 100/3.6

Globe Newswire - November 21

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Xultophy® 100/3.6. Xultophy® 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).

Window size: x
Viewport size: x